1
|
Cassano N, Caccavale S, Vena GA, Argenziano G. Body Mass Index and Melanoma Prognosis. Dermatol Pract Concept 2021; 11:e2021106. [PMID: 34631264 DOI: 10.5826/dpc.1104a106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/05/2021] [Indexed: 10/31/2022] Open
Abstract
Introduction Obesity has been suggested as a risk factor in the progression of malignancies, including melanoma. Most studies defined obesity using body mass index (BMI), although the index is considered an imperfect measure of body composition. Objective The aim of this article is to examine whether BMI can impact on the prognosis of cutaneous melanoma, regardless of anti-tumor therapy. The relationship between BMI and specific prognostic factors in melanoma patients has been reviewed. Methods Literature search was conducted on PubMed using the terms "melanoma" and "body mass index" or "obesity". We selected articles, published up to 30 November 2020, examining the prognostic aspects of melanoma. Articles evaluating the risk and incidence of melanoma were excluded as well as studies regarding morbidity and complications following surgical procedures, or those performed in metastatic melanoma patients treated with anti-tumor therapies. Results Mixed results have emerged from studies assessing the clinical outcomes in melanoma patients in relation to BMI. More consistent data seem to support the relationship between BMI and Breslow thickness. Conclusions Studies that focus specifically on the link between obesity and melanoma prognosis are limited; further research is needed to deepen our knowledge on this link.
Collapse
Affiliation(s)
- Nicoletta Cassano
- Dermatology and Venereology Private Practice, Bari, Italy.,Dermatology and Venereology Private Practice, Barletta, Italy
| | - Stefano Caccavale
- Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Gino A Vena
- Dermatology and Venereology Private Practice, Bari, Italy.,Dermatology and Venereology Private Practice, Barletta, Italy
| | | |
Collapse
|
2
|
Bradbury KE, Appleby PN, Tipper SJ, Travis RC, Allen NE, Kvaskoff M, Overvad K, Tjønneland A, Halkjær J, Cervenka I, Mahamat‐Saleh Y, Bonnet F, Kaaks R, Fortner RT, Boeing H, Trichopoulou A, La Vecchia C, Stratigos AJ, Palli D, Grioni S, Matullo G, Panico S, Tumino R, Peeters PH, Bueno‐de‐Mesquita HB, Ghiasvand R, Veierød MB, Weiderpass E, Bonet C, Molina E, Huerta JM, Larrañaga N, Barricarte A, Merino S, Isaksson K, Stocks T, Ljuslinder I, Hemmingsson O, Wareham N, Khaw K, Gunter MJ, Rinaldi S, Tsilidis KK, Aune D, Riboli E, Key TJ. Circulating insulin-like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition. Int J Cancer 2019; 144:957-966. [PMID: 30191956 PMCID: PMC6481548 DOI: 10.1002/ijc.31854] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 07/23/2018] [Accepted: 07/25/2018] [Indexed: 01/10/2023]
Abstract
Insulin-like growth factor-I (IGF-I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour development. Previous prospective studies have shown that higher circulating concentrations of IGF-I are associated with a higher risk of cancers at specific sites, including breast and prostate. No prospective study has examined the association between circulating IGF-I concentrations and melanoma risk. A nested case-control study of 1,221 melanoma cases and 1,221 controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of 520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios (ORs) for incident melanoma in relation to circulating IGF-I concentrations, measured by immunoassay. Analyses were conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity and in women only, use of menopausal hormone therapy. There was no significant association between circulating IGF-I concentration and melanoma risk (OR for highest vs lowest fifth = 0.93 [95% confidence interval [CI]: 0.71 to 1.22]). There was no significant heterogeneity in the association between IGF-I concentrations and melanoma risk when subdivided by gender, age at blood collection, BMI, height, age at diagnosis, time between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity≥0.078). We found no evidence for an association between circulating concentrations of IGF-I measured in adulthood and the risk of melanoma.
Collapse
Affiliation(s)
- Kathryn E. Bradbury
- Cancer Epidemiology Unit, Nuffield Department of Population HealthUniversity of OxfordOxfordUnited Kingdom
- National Institute for Health InnovationSchool of Population Health, The University of AucklandAucklandNew Zealand
| | - Paul N. Appleby
- Cancer Epidemiology Unit, Nuffield Department of Population HealthUniversity of OxfordOxfordUnited Kingdom
| | - Sarah J. Tipper
- Cancer Epidemiology Unit, Nuffield Department of Population HealthUniversity of OxfordOxfordUnited Kingdom
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Population HealthUniversity of OxfordOxfordUnited Kingdom
| | - Naomi E. Allen
- Clinical Trial Service Unit, Nuffield Department of Population HealthUniversity of OxfordOxfordUnited Kingdom
| | - Marina Kvaskoff
- CESPFac. de médecine ‐ Univ. Paris‐Sud, Fac. de médecine ‐ UVSQ, INSERM, Université Paris‐SaclayVillejuifFrance
- Gustave RoussyVillejuifFrance
| | - Kim Overvad
- Department of Public Health, Section for EpidemiologyAarhus UniversityAarhusDenmark
| | | | - Jytte Halkjær
- Danish Cancer Society Research CenterCopenhagenDenmark
| | - Iris Cervenka
- CESPFac. de médecine ‐ Univ. Paris‐Sud, Fac. de médecine ‐ UVSQ, INSERM, Université Paris‐SaclayVillejuifFrance
- Gustave RoussyVillejuifFrance
| | - Yahya Mahamat‐Saleh
- CESPFac. de médecine ‐ Univ. Paris‐Sud, Fac. de médecine ‐ UVSQ, INSERM, Université Paris‐SaclayVillejuifFrance
- Gustave RoussyVillejuifFrance
| | - Fabrice Bonnet
- CESPFac. de médecine ‐ Univ. Paris‐Sud, Fac. de médecine ‐ UVSQ, INSERM, Université Paris‐SaclayVillejuifFrance
- Gustave RoussyVillejuifFrance
- CHU RennesUniversité de Rennes 1RennesFrance
| | - Rudolf Kaaks
- Division of Cancer EpidemiologyGerman Cancer Research CenterHeidelbergGermany
| | - Renée T. Fortner
- Division of Cancer EpidemiologyGerman Cancer Research CenterHeidelbergGermany
| | - Heiner Boeing
- Department of EpidemiologyGerman Institute of Human Nutrition Potsdam‐Rehbrücke (DIfE)NuthetalGermany
| | | | - Carlo La Vecchia
- Hellenic Health FoundationAthensGreece
- Department of Clinical Sciences and Community HealthUniversità degli Studi di Milano, Milan, Italy
| | - Alexander J. Stratigos
- Hellenic Health FoundationAthensGreece
- 1st Department of Dermatology and VenereologyNational and Kapodistrian University of Athens School of MedicineAndreas Sygros HospitalAthensGreece
| | - Domenico Palli
- Cancer Risk Factors and Life‐Style Epidemiology UnitInstitute for Cancer Research, Prevention and Clinical NetworkISPRO, FlorenceItaly
| | - Sara Grioni
- Epidemiology and Prevention UnitFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
| | - Giuseppe Matullo
- Department of Medical SciencesUniversity of TorinoTorinoItaly
- Italian Institute for Genomic Medicine (IIGM/fka HuGeF)TorinoItaly
| | - Salvatore Panico
- Dipartmento di Medicina Clinica E ChirurgiaFederico II UniversityNaplesItaly
| | - Rosario Tumino
- Cancer Registry and Histopathology Department"Civic ‐ M.P. Arezzo" Hospital, ASPRagusaItaly
| | - Petra H. Peeters
- Department of EpidemiologyJulius Center for Health Sciences and Primary Care, University Medical Center UtrechtUtrechtthe Netherlands
| | - H. Bas Bueno‐de‐Mesquita
- Department of Epidemiology and BiostatisticsThe School of Public Health, Imperial College London, St Mary's CampusW2 1PG, LondonUnited Kingdom
- Department of Social and Preventive MedicineFaculty of Medicine, University of Malaya50603Kuala LumpurMalaysia
- Department for Determinants of Chronic Diseases (DCD)National Institute for Public Health and the Environment (RIVM)BilthovenThe Netherlands
| | - Reza Ghiasvand
- Oslo Centre for Biostatistics and Epidemiology, Department of BiostatisticsInstitute of Basic Medical Sciences, University of OsloNorway
| | - Marit B. Veierød
- Oslo Centre for Biostatistics and Epidemiology, Department of BiostatisticsInstitute of Basic Medical Sciences, University of OsloNorway
| | - Elisabete Weiderpass
- Department of Community MedicineFaculty of Health Sciences, UiT, The Arctic University of NorwayTromsøNorway
- Department of Research, Cancer Registry of NorwayInstitute of Population‐Based Cancer ResearchOsloNorway
- Genetic Epidemiology GroupFolkhälsan Research Center and Faculty of Medicine, University of HelsinkiFinland
- Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
| | - Catalina Bonet
- Unit of Nutrition and Cancer, Cancer Epidemiology Research ProgramCatalan Institute of Oncology‐IDIBELL, L'Hospitalet de LlobregatBarcelonaSpain
| | - Elena Molina
- Escuela Andaluza de Salud PúblicaInstituto de Investigación Biosanitaria ibs, GRANADA, Hospitales Universitarios de Granada/Universidad de GranadaGranadaSpain
- CIBER de Epidemiología y Salud Pública (CIBERESP)MadridSpain
| | - José M. Huerta
- CIBER de Epidemiología y Salud Pública (CIBERESP)MadridSpain
- Department of EpidemiologyMurcia Regional Health CouncilMurciaSpain
| | - Nerea Larrañaga
- CIBER de Epidemiología y Salud Pública (CIBERESP)MadridSpain
- Basque Regional Health DepartmentPublic Health Division of Gipuzkoa‐BIODONOSTIA, San Sebastián, Spain
| | - Aurelio Barricarte
- CIBER de Epidemiología y Salud Pública (CIBERESP)MadridSpain
- Navarra Public Health InstitutePamplonaSpain
| | | | - Karolin Isaksson
- Department of Clinical Sciences SurgeryBreast and Melanoma Unit, Lund University, Skåne University HospitalLundSweden
| | - Tanja Stocks
- Department of Clinical Sciences MalmöLund UniversitySweden
| | - Ingrid Ljuslinder
- Department of Radiation Sciences, OncologyNorrlands University HospitalUmeåSweden
| | - Oskar Hemmingsson
- Department of Surgical and perioperative Sciences/SurgeryUmeå UniversityUmeåSweden
| | - Nick Wareham
- MRC Epidemiology UnitUniversity of CambridgeCambridgeUnited Kingdom
| | - Kay‐Tee Khaw
- Department of Public Health and Primary CareUniversity of CambridgeCambridgeUnited Kingdom
| | - Marc J. Gunter
- Section of Nutrition and MetabolismInternational Agency for Research on Cancer, World Health OrganizationLyonFrance
| | - Sabina Rinaldi
- Section of Nutrition and MetabolismInternational Agency for Research on Cancer, World Health OrganizationLyonFrance
| | - Konstantinos K. Tsilidis
- Department of Epidemiology and Biostatistics, Faculty of MedicineSchool of Public Health, Imperial College LondonLondonUnited Kingdom
- Department of Hygiene and EpidemiologyUniversity of Ioannina School of MedicineIoanninaGreece
| | - Dagfinn Aune
- Department of Epidemiology and Biostatistics, Faculty of MedicineSchool of Public Health, Imperial College LondonLondonUnited Kingdom
- Department of NutritionBjørknes University CollegeOsloNorway
- Department of EndocrinologyMorbid Obesity and Preventive Medicine, Oslo University HospitalOsloNorway
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, Faculty of MedicineSchool of Public Health, Imperial College LondonLondonUnited Kingdom
| | - Timothy J. Key
- Cancer Epidemiology Unit, Nuffield Department of Population HealthUniversity of OxfordOxfordUnited Kingdom
| |
Collapse
|
3
|
Park SL, Setiawan VW, Kanetsky PA, Zhang ZF, Wilkens LR, Kolonel LN, Le Marchand L. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma. Cancer Causes Control 2011; 22:1267-75. [PMID: 21698457 DOI: 10.1007/s10552-011-9800-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2011] [Accepted: 06/13/2011] [Indexed: 10/18/2022]
Abstract
We examined the relationship of insulin-like growth factor-I (IGF-I) and its primary growth factor, IGF binding protein-3 (IGFBP-3) with malignant melanoma using interview data and sera from cases (n = 286) and controls (n = 289) in a population-based case-control study conducted in 1986-1992 on Oahu, Hawaii. Serum IGF-I and IGFBP-3 concentrations were measured by ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression and adjusting for age, sex, education, number of blistering sunburns, ability to tan, hair color, energy intake, BMI, height, smoking status, and drinking status. An inverse relationship was found between IGF-I concentration and melanoma (OR for upper vs. lower tertile: 0.44, 95% CI: 0.25-0.79), but clear associations were not observed between malignant melanoma and upper tertiles of IGFBP-3 and the IGF-1/IGFBP-3 molar ratio. The inverse association with IGF-I was strongest among subjects who did not report a history of non-melanoma skin cancer (NMSC) (OR for ≥ vs. < median: 0.39, 95% CI: 0.24-0.65), and a positive association was found among those with such a history (OR: 3.6, 95% CI: 1.0-13; p (interaction) = 0.0035). Our findings observed here between serum IGF-I and malignant melanoma warrants replication in studies with a larger sample size and a prospective design.
Collapse
Affiliation(s)
- Sungshim Lani Park
- Epidemiology Program, University of Hawaii Cancer Center, 1236 Lauhala Street, Suite 407, Honolulu, HI 96813, USA.
| | | | | | | | | | | | | |
Collapse
|
4
|
Capoluongo E. Insulin-like growth factor system and sporadic malignant melanoma. THE AMERICAN JOURNAL OF PATHOLOGY 2010; 178:26-31. [PMID: 21224039 DOI: 10.1016/j.ajpath.2010.11.004] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/25/2010] [Revised: 07/15/2010] [Accepted: 08/10/2010] [Indexed: 11/18/2022]
Abstract
Insulin and insulin-like growth factors (IGFs) are important regulators of energy metabolism and growth. Several findings have outlined an important role played by this family of molecules in both tumor maintenance and development. Despite the established contribution of the IGF system in carcinogenesis, little and contrasting data have been reported concerning the intertwined relationships between melanoma and this family of molecules. The present minireview aims to summarize the main topics and evidence concerning this malignant skin cancer, with a focus on the following: i) melanoma and cell proliferation effects induced by the IGF system, ii) in vitro and in vivo experimental data, and iii) targeting studies. Because of consistent findings regarding the role of the IGF-1 receptor in the modulation of IGF-1 activity, possible therapeutic strategies combining the use of antisense oligonucleotides against IGF-1 receptor mRNA could be applied in the future.
Collapse
Affiliation(s)
- Ettore Capoluongo
- Laboratory of Clinical Molecular Diagnostic, Institute of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy.
| |
Collapse
|
5
|
Greco C, Vitelli G, Vercillo G, Vona R, Giannarelli D, Sperduti I, Pisani F, Capoluongo E, Petti MC, Ameglio F. Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2009; 28:35. [PMID: 19284554 PMCID: PMC2663546 DOI: 10.1186/1756-9966-28-35] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Accepted: 03/10/2009] [Indexed: 01/04/2023]
Abstract
Background Serum levels of IGF-I in patients affected with multiple myeloma (MM) have been scarcely studied. The present study is aimed to explore this point comparing 55 healthy subjects, 71 monoclonal gammopaties of uncertain significance (MGUS) and 77 overt MM patients. In the same subjects, basic FGF and VEGF, have been detected. All three mediators were analyzed in function of K-ras mutation and melphalan response. Concerning IGF-I, two representative monitoring examples have also been added. Methods Cytokine determinations were performed by commercially available ELISA kits, while K12-ras mutation was investigated on genomic DNA isolated from bone marrow cell specimens by RFLP-PCR assay. Results Significant reductions of IGF-I levels were observed in MGUS and MM as compared with healthy controls. In addition, MM subjects showed significantly decreased serum IGF-I levels than MGUS. Conversely, increasing levels were observed for bFGF and VEGF, molecules significantly correlated. A multivariate analysis corrected for age and gender confirmed the significant difference only for IGF-I values (P = 0.01). K12-ras mutation was significantly associated with malignancy, response to therapy and with significantly increased serum bFGF levels. Conclusion IGF-I reduction in the transition: Controls→MGUS→MM and changes observed over time suggest that IGF-I should be furtherly studied in future clinical trials as a possible monitoring marker for MM.
Collapse
Affiliation(s)
- Claudia Greco
- Clinical Pathology Service, Polo Oncologico Regina Elena, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|